Teva Pharmaceuticals received U.S. FDA approval for generic versions of both the EpiPen and EpiPen Jr — the first generic competitor to Mylan's auto-injector.
It’s a big win for Teva, as the FDA previously declined to approve its treatment for life-threatening allergic reactions back in 2016.
The approval also comes after months of spot shortages of Mylan’s EpiPen and Mylan’s authorized generic.
While Teva hasn’t provided any details about specific timing or the planned price, according to a CNBC report, the drugmaker said it is “applying our full resources to this important launch in the coming months and eager to being supplying the market.”
Read the FDA statement